Canada markets closed

Onxeo SA (OXNXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.67000.0000 (0.00%)
At close: 03:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6700
Open0.6700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6700 - 0.6700
52 Week Range0.4800 - 0.8500
Volume565
Avg. Volume0
Market Cap35.588M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Onxeo: Publication of the 2021 Annual Financial Report

    PARIS, April 28, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the publication of the Company’s 2020 annual financial report.

  • Business Wire

    Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

    PARIS, April 07, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer. Dr. Agarwal succeeds Julien Miara, a Principal at Invus SAS, who was named interim CEO in January 2022.

  • Business Wire

    Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million

    PARIS, April 06, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reported its consolidated results for the fiscal year ending December 31, 2021 and announced additional funding of €12 million subscribed by its longstanding shareholders Invus and Financière de la Monta